Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...
Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results